Isabelle Johansson1, Ulf Dahlström2, Magnus Edner1, Per Näsman3, Lars Rydén1, Anna Norhammar1. 1. Cardiology Unit, Department of Medicine Solna, Karolinska Institute, Stockholm. 2. Department of Cardiology and Department of Medical and Health Sciences, Linkoping University, Linkoping, Sweden. 3. Center for Safety Research, KTH Royal Institute of Technology, Stockholm, Sweden.
Abstract
OBJECTIVE: To test the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart failure (HF) with and without diabetes in the Swedish Heart Failure Registry. METHODS: Patients with (n=8809) and without (n=27 465) type 2 diabetes (T2DM) included in the Swedish Heart Failure Registry (2003-2011) were followed for mortality during a median follow-up of 1.9 years (range 0-8.7 years). All-cause mortality, differences in background and HF characteristics were analysed in women and men with and without T2DM and with a special regard to different age groups. RESULTS: Of 36 274 patients, 24% had T2DM and 39% were women. In patients with T2DM, women were older than men (78 years vs 73 years), more frequently had hypertension, renal dysfunction and preserved ventricular function. Regardless of T2DM status, women with reduced ventricular function, compared with their male counterparts, were less frequently offered, for example, ACE inhibitors/angiotensin receptor II blockers (ARB). Absolute mortality was 48% in women with T2DM, 40% in women without; corresponding male mortality rates were 43% and 35%, respectively. Kaplan-Meier curves revealed shorter longevity in women with T2DM but female sex did not remain a significant mortality predictor following adjustment (OR 95% CI 0.90; 0.79 to 1.03). In those without T2DM, women compared with men lived longer; this pattern remained after adjustment (OR 0.72; 0.66 to 0.78). T2DM was a stronger predictor of mortality in women (OR 1.72; 1.53 to 1.94) than in men (OR 1.47; 1.34 to 1.61). CONCLUSIONS: T2DM is a strong mortality predictor in men and women with HF, somewhat stronger in women. The shorter survival time in women with T2DM and HF related to comorbidities rather than sex per se. Evidence-based management was less prevalent in women. Mechanisms behind these findings remain incompletely understood and need further attention. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To test the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart failure (HF) with and without diabetes in the Swedish Heart Failure Registry. METHODS:Patients with (n=8809) and without (n=27 465) type 2 diabetes (T2DM) included in the Swedish Heart Failure Registry (2003-2011) were followed for mortality during a median follow-up of 1.9 years (range 0-8.7 years). All-cause mortality, differences in background and HF characteristics were analysed in women and men with and without T2DM and with a special regard to different age groups. RESULTS: Of 36 274 patients, 24% had T2DM and 39% were women. In patients with T2DM, women were older than men (78 years vs 73 years), more frequently had hypertension, renal dysfunction and preserved ventricular function. Regardless of T2DM status, women with reduced ventricular function, compared with their male counterparts, were less frequently offered, for example, ACE inhibitors/angiotensin receptor II blockers (ARB). Absolute mortality was 48% in women with T2DM, 40% in women without; corresponding male mortality rates were 43% and 35%, respectively. Kaplan-Meier curves revealed shorter longevity in women with T2DM but female sex did not remain a significant mortality predictor following adjustment (OR 95% CI 0.90; 0.79 to 1.03). In those without T2DM, women compared with men lived longer; this pattern remained after adjustment (OR 0.72; 0.66 to 0.78). T2DM was a stronger predictor of mortality in women (OR 1.72; 1.53 to 1.94) than in men (OR 1.47; 1.34 to 1.61). CONCLUSIONS: T2DM is a strong mortality predictor in men and women with HF, somewhat stronger in women. The shorter survival time in women with T2DM and HF related to comorbidities rather than sex per se. Evidence-based management was less prevalent in women. Mechanisms behind these findings remain incompletely understood and need further attention. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Andrea Salzano; Roberta D'Assante; Eduardo Bossone; Alberto M Marra; Antonio Cittadini; Massimo Iacoviello; Vincenzo Triggiani; Giuseppe Rengo; Francesco Cacciatore; Ciro Maiello; Giuseppe Limongelli; Daniele Masarone; Angela Sciacqua; Pasquale Perrone Filardi; Antonio Mancini; Maurizio Volterrani; Olga Vriz; Roberto Castello; Andrea Passantino; Michela Campo; Pietro A Modesti; Alfredo De Giorgi; Michele Arcopinto; Paola Gargiulo; Maria Perticone; Annamaria Colao; Salvatore Milano; Agnese Garavaglia; Raffaele Napoli; Toru Suzuki Journal: Cardiovasc Diabetol Date: 2022-06-16 Impact factor: 8.949
Authors: Bernard Zinman; Silvio E Inzucchi; Christoph Wanner; Uwe Hehnke; Jyothis T George; Odd Erik Johansen; David Fitchett Journal: Diabetologia Date: 2018-04-30 Impact factor: 10.122
Authors: Silvio E Inzucchi; Kamlesh Khunti; David H Fitchett; Christoph Wanner; Michaela Mattheus; Jyothis T George; Anne Pernille Ofstad; Bernard Zinman Journal: J Clin Endocrinol Metab Date: 2020-09-01 Impact factor: 5.958
Authors: Saraschandra Vallabhajosyula; Dhiran Verghese; Viral K Desai; Pranathi R Sundaragiri; Virginia M Miller Journal: Cardiovasc Res Date: 2022-02-21 Impact factor: 10.787
Authors: Muhammed T Gürgöze; Onno P van der Galiën; Marlou A M Limpens; Stefan Roest; René C Hoekstra; Arne S IJpma; Jasper J Brugts; Olivier C Manintveld; Eric Boersma Journal: ESC Heart Fail Date: 2020-11-28